Form 4: Director Tober Converts SCPH Options in Merger

scPharmaceuticals Director William Tober converted all his stock options into cash and Contingent Value Rights following the completion of a tender offer by MannKind Corporation.

Summary

• Director William Tober reported the disposition of all his scPharmaceuticals Inc. stock options.
• The disposition occurred on October 7, 2025, in connection with the completion of a tender offer by MannKind Corporation for scPharmaceuticals Inc. common stock.
• Options with an exercise price less than $5.35 were cancelled and converted into a cash payment and one Contingent Value Right (CVR) per share.
• Tober's disposed options included 30,000 shares at an exercise price of $3.85, 19,750 shares at $4.11, and 16,300 shares at $4.53.
• Following these transactions, Tober beneficially owns 0 derivative securities.

Sentiment

Score: 7

Explanation: The filing reports the expected outcome of a merger, providing a defined cash value and CVRs for in-the-money options. While it signifies the end of scPharmaceuticals as an independent entity, the terms appear to be executed as planned, offering a structured exit for option holders.

Positives

• The merger agreement provides a clear and defined exit strategy for in-the-money option holders.
• Option holders receive a cash payment based on the difference between $5.35 and their exercise price, providing immediate liquidity.
• The inclusion of Contingent Value Rights (CVRs) offers potential additional value tied to future events.

Negatives

• scPharmaceuticals Inc. is being acquired, indicating a loss of its independent public trading status.
• The cancellation of options means no future upside from the original options beyond the merger terms.
• The value of the Contingent Value Rights (CVRs) is uncertain and depends on future performance or milestones.

Risks

• The ultimate value of the Contingent Value Rights (CVRs) is speculative and subject to future events or performance milestones.
• Shareholders and option holders are bound by the terms of the Merger Agreement, which may limit future upside potential compared to an independent company.
• There is a risk associated with the execution and realization of the CVRs, which are not publicly traded securities.

Future Outlook

The filing indicates the completion of a tender offer and merger, suggesting scPharmaceuticals Inc. will no longer be an independent publicly traded entity. The future outlook for option holders is tied to the cash payout received and the uncertain value realization of the Contingent Value Rights.

Industry Context

This transaction is part of the ongoing consolidation within the pharmaceutical and biotechnology sectors, where larger companies often acquire smaller ones for their pipeline, technology, or market access. MannKind Corporation's acquisition of scPharmaceuticals indicates a strategic move to integrate assets or expand market presence.

Comparison to Industry Standards

• Merger agreements commonly include specific provisions for the treatment of outstanding equity awards, such as stock options, which is standard practice in corporate acquisitions.
• The use of Contingent Value Rights (CVRs) is a recognized mechanism in biotech mergers to bridge valuation gaps or provide additional consideration tied to future milestones, such as regulatory approvals or sales targets.
• The cash-out of in-the-money options at a fixed price, as seen with the $5.35 per share, is a typical approach to simplify the equity structure and provide liquidity to option holders post-merger.

Corporate Governance

Related Party Transactions

• The conversion of Director William Tober's stock options into cash and CVRs is a transaction directly related to the merger agreement between scPharmaceuticals Inc. and MannKind Corporation, involving an insider (director) and the acquiring entity.

Stakeholder Impact

• Shareholders who tendered their shares received cash consideration as per the merger terms.
• Option holders, such as Director Tober, received a cash payout for their in-the-money options and Contingent Value Rights, providing a defined exit value.
• The merger will likely impact employees, though specific details are not provided in this filing.

Next Steps

• Realization of value from Contingent Value Rights (CVRs) will depend on future events and performance milestones.
• scPharmaceuticals Inc. will likely cease to be a publicly traded company following the completion of the merger.

Key Dates

Recommendation

The company is undergoing an acquisition by MannKind Corporation, with a tender offer completed on October 7, 2025. For existing shareholders and option holders, the primary action is to understand the terms of the merger, including the cash payout and the potential future value of Contingent Value Rights (CVRs). There is no independent trading opportunity for scPharmaceuticals stock as it is being acquired. The recommendation to 'hold' applies to the CVRs, awaiting their potential future value realization.

Keywords

scPharmaceuticals, SCPH, MannKind Corporation, Merger, Tender Offer, Stock Options, Form 4, Insider Transaction, Corporate Acquisition, Contingent Value Rights, CVR